-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on HeartSciences, Lowers Price Target to $14

Benzinga·03/18/2025 10:07:11
Listen to the news
Ascendiant Capital analyst Lucas Ward maintains HeartSciences (NASDAQ:HSCS) with a Buy and lowers the price target from $15 to $14.